The cost of angina: how do we measure it? How do we improve it?-Reference-Cited by-同舟云学术

The cost of angina: how do we measure it? How do we improve it?

Published:2019-10-21 Issue: Volume: Page:
ISSN:2058-5225
Container-title:European Heart Journal - Quality of Care and Clinical Outcomes
language:en
Short-container-title:

Author:

Jolicoeur Etienne Marc¹,Henry Timothy D²^ORCID

Affiliation:

1. Department of Medicine, Montreal Heart Institute, Université de Montréal, Québec, Canada

2. The Christ Hospital Heart and Vascular Center/The Lindner Center for Research and Education, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine,Health Policy

Link

http://academic.oup.com/ehjqcco/advance-article-pdf/doi/10.1093/ehjqcco/qcz058/30251945/qcz058.pdf

Reference10 articles.

1. Treatment of refractory angina in patients not suitable for revascularization;Henry;Nat Rev Cardiol,2014

2. Management of patients with refractory angina: Canadian Cardiovascular Society/Canadian Pain Society joint guidelines;McGillion;Can J Cardiol,2012

3. Clinical and research issues regarding chronic advanced coronary artery disease part II: trial design, outcomes, and regulatory issues;Jolicoeur;Am Heart J,2008

4. Long-term survival in patients with refractory angina;Henry;Eur Heart J,2013

5. CD34+ cell therapy for no-option refractory disabling angina: time for FDA approval?;Benck;Cardiovasc Revasc Med,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction;Circulation: Cardiovascular Interventions;2022-02

2. The Placebo Effect on Symptoms, Quality of Life, and Functional Outcomes in Patients With Angina Pectoris: A Meta-analysis of Randomized Placebo-Controlled Trials;Canadian Journal of Cardiology;2022-01